Visual Evoked Potential Findings of Sjogren's Syndrome
Journal of Ophthalmic and Optometric Sciences,
Vol. 4 No. 1 (2020),
6 January 2020
,
Page 13-17
https://doi.org/10.22037/joos.v4i1.36657
Abstract
Background: Sjogren’s syndrome is one of the most common autoimmune diseases. These diseases can affect the entire body. Visual system involvement, i.e., dry eye is most common among these Patients. Visual pathway is a part of visual system may be affected in these patients. The aim of present work is to look for probable visual pathway disturbance of Sjogren’s syndrome using visual evoked potential.
Material and Methods: Forty eyes (20 Sjogren’s female patients) with age in between 45-55 years were chosen for this study. Implicit time and amplitude of VEP, P100 peak was measured in patient group. Same procedure was repeated for 20 healthy subjects with matched age and sex condition.
Results: The mean age of the patient group was 49.6 ± 3.06 and in case of healthy population it was 50.15 ± 3.28. The difference between two groups was not significant. In case of visual acuity, the difference between two groups was not statistically significant i.e., both groups had 10⁄10 BCVA. The mean values for implicit time were 100.05 ± 3.8 and 99.55 ± 3.54 in patient and healthy groups respectively.
In case of amplitude the values were 5.4 ± 1.44 and 5.2 ± 1.41 in patient and healthy groups respectively. The calculation does not show statistically significant changes between two parameters VEP, P100 peak.
Conclusion: Sjogren’s syndrome does not have any adverse effect on visual pathway as far as latency and amplitude of visual evoked potential P100 is concerned.
Keywords: Sjogren’s Syndrome; Visual Pathway; Visual Evoked Potential.
- Sjogren’s syndrome
- visual pathway
- visual evoked potential
How to Cite
References
Vivino FB, Bunya VY, Massaro-Giordano G, Johr CR, Giattino SL, Schorpion A, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clinical Immunology (Orlando, Fla). 2019;203:81-121.
Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjögren’s syndrome. Current allergy and asthma reports. 2005;5(4):327-32.
Jack LS, Benson C, Sadiq MA, Rizzo WB, Margalit E. Segmentation of retinal layers in Sjögren–Larsson syndrome. Ophthalmology. 2015;122(8):1730-2.
Aslam SA, Sheth HG. Ocular features of Sjogren–Larsson syndrome. Clinical & experimental ophthalmology. 2007;35(1):98-9.
Saatci AO, Özbek Z, Köse S, Durak I, Kavukçu S. An unusual central retinal dystrophy associated with ichthyosis vulgaris. Ophthalmic Genet. 2000;21(2):101-7.
Fang P-C, Chen Y-J, Tu Y-F. Neurophysiological studies in a case of Sjögren-Larsson syndrome. Acta Paediatrica Taiwanica= Taiwan er ke yi xue hui za zhi. 2003;44(6):356-9.
Sharma P, Chaudhuri Z, Raina UK, Ghosh B, Sethi S. Abnormal Ocular Electrophysiology in Sjögren–Larsson Syndrome. Journal of Pediatric Ophthalmology & Strabismus. 2009;46(1):42-4.
Dziadkowiak E, Sebastian A, Wieczorek M, Pokryszko-Dragan A, Madej M, Waliszewska-Prosół M, et al. Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome. Journal of clinical medicine. 2021;10(18):4196.
Ojani F, Shushtarian SMM, Shojaei A, Naghib J. Visual Evoked Potential Findings of Bardet-Biedl Syndrome. Journal of Ophthalmology and Research. 2021;4(3):254-7.
Shushtarian S, Kalantari AS, Tajik F, Adhami-Moghadam F. Effect of occupational vibration on visual pathway measured by visual evoked potentials. Journal of Ophthalmic and Optometric Sciences. 2017;1(5):7-11.
Keramti S, Ojani F, Shushtarian SMM, Shojaei A, Mohammad-Rabei H. Early Diagnosis of Pathological Changes in Visual System of Prolactinoma Patients Using Visual Evoked Potential. Journal of Ophthalmology and Research. 2021;4(3):289-93.
Shushtarian SMM, Adhami-Moghadam F, Adhami-Moghadam P, Abdolhoseinpour H. Electrophysiological Eye Examination Changes in a Patient with Sjogren's Syndrome. Journal of Ophthalmic and Optometric Sciences. 2018;2(1):40-3.
Willemsen MA, Cruysberg JR, Rotteveel JJ, Aandekerk AL, Van Domburg PH, Deutman AF. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren-Larsson syndrome. Am J Ophthalmol. 2000;130(6):782-9.
Hietaharju A, Yli‐Kerttula U, Häkkinen V, Frey H. Nervous system manifestations in Sjögren's syndrome. Acta neurologica scandinavica. 1990;81(2):144-52.
- Abstract Viewed: 292 times
- pdf Downloaded: 117 times
